Effect of Zoledronic Acid as Anti-Cancer Treatment in Metastatic Breast Cancer Patients (MACS1295)

Novartis

Status and phase: Completed; Phase 4

Conditions: First or Second Line HER2-negative Breast Cancer; Metastatic Disease Without Bone Metastasis

Treatments: Drug: Standard Therapy; Drug: Zoledronic acid

Study type: Interventional

Funder types: Industry

Identifiers

NCT01129336

CZOL446EUS147

Details and patient eligibility

About

This study will evaluate zoledronic acid's anti-cancer effects and Circulating Tumor Cell (CTCs) measurements in patients with HER2-negative metastatic breast cancer without bone metastasis.

Enrollment: 44 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent

• Female patients (age ≥18 years)

• HER2-negative metastatic breast cancer (stage IV)

• Patients will be receiving chemotherapy or hormonal therapy

• Patients with no bone metastasis and ≤1 prior treatments for metastatic breast cancer. Patients with newly diagnosed metastatic breast cancer may have received adjuvant or neoadjuvant chemotherapy as long as treatment was completed ≥12 months prior to relapse.

• Asymptomatic brain metastasis is permitted if all of the following criteria are met:

  1. no sign of clinical progression or known progression of brain metastasis
  2. off steroids for at least 2 weeks prior to study enrollment

• Stable renal function: two serum creatinine determinations of <3 mg/dL, obtained no less than 7 days apart (one value may be obtained within 6 weeks prior to Screening; the second must be obtained during Screening)

• ECOG performance status of 0 or 1

• Life expectancy of ≥ 6 months

• Negative serum pregnancy test

• Ability and willingness to comply with all study requirements

Exclusion criteria

• Known hypersensitivity to zoledronic acid or other bisphosphonates
• Patients with history of another malignancy within the last two years prior to study enrollment, except cured basal cell carcinoma of the skin or excised carcinoma in site of the cervix
• Use of concurrent investigational agents is prohibited. Prior use of investigational agents is permitted if discontinued ≥30 days prior to Screening.
• No prior therapy with an antiresorptive agent
• Patients with active brain metastases or meningeal metastases
• Current or recent (in the six months prior to initial study drug treatment) severe cardiovascular disease (defined as uncontrolled congestive heart failure), hypertension refractory to treatment, or poorly controlled Type I/II diabetes mellitus
• Current active dental problems including dental abscess or infection of the jawbone (maxilla or mandible) or a current or prior diagnosis of osteonecrosis of the jaw
• Patients who have received radiotherapy ≤ 4 weeks prior to study enrollment or who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤ 2 weeks prior to study enrollment is allowed
• Patients who have undergone major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) ≤ 4 weeks prior to study enrollment or who have not recovered from side effects of such therapy
• Diminished renal capacity: calculated creatinine clearance (CrCl) <30 mL/min (based on Cockcroft-Gault formula)
• Corrected (i.e., adjusted for serum albumin) serum calcium of <8.0 mg/dL (2.00 mmol/L) or ≥ 12 mg/dL (3.00 mmol/L)
• Pregnant or breast-feeding females
• Women of child-bearing potential who are not willing/able to use effective methods of birth control (e.g., abstinence, oral contraceptives or implants, IUD, vaginal diaphragm or sponge, or condom with spermicide)
• History of non-compliance to medical regimens and/or patients who are considered unreliable
• History of bone metabolism diseases

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

44 participants in 2 patient groups

Patients without bone metastases

Experimental group

Description:

Patients with no bone metastasis were randomized into a 1:1 ratio to standard therapy plus zoledronic acid 4mg IV Zoledronic acid administration monthly during Months 1-18.

Treatment:

Drug: Zoledronic acid

Patients with bone metastases

Experimental group

Description:

Patients with bone metastasis received standard therapy + zoledronic acid for 18 months (discontinued upon disease progression/secondary malignancy)

Treatment:

Drug: Standard Therapy